bioRxiv Science⌕ Search

Biology subjects

Metts, J. M.

Publications and source records attributed to Metts, J. M..

2 recordsLinked to original sources

Enhancing ML-based binder design with high-throughput screening: a comparison of mRNA and yeast display technologies

Recent advances in machine learning (ML)-based protein design methods have enabled the rapid in silico generation of large libraries of miniprotein binders with minimal manual input. While computational design capacity has scaled rapidly, experimental validation methods have lagged, creating a bottleneck in binder discovery pipelines. Here, we apply mRNA display to screen an ML-designed miniprotein binder library and directly compare its performance with the more widely used yeast surface display platform using a single shared DNA library. We screened 2,009 designs targeting the platelet receptor TLT-1 and 3,159 designs targeting the immune receptor B7-H3 across both platforms. While both selection methods reliably identified functional binders, we found that mRNA display preferentially enriched binders with slower dissociation rates. In addition, mRNA display achieved higher library coverage than yeast display, likely rescuing functional designs that are penalized in a cell-based expression system. Biophysical characterization of selected binders from both platforms revealed strong binding affinities and high thermal stabilities. These results showcase the power of integrating ML-based computational design tools with rapid in vitro selection technologies, providing a scalable framework for therapeutic miniprotein discovery. IMPORTANCEMiniprotein binders offer major advantages as next-generation therapeutics, including small size, high stability, and efficient production. In this work, we conduct a side-by-side comparison of mRNA and yeast display as platforms for high-throughput evaluation of de novo miniprotein binders. The binders generated here serve as starting points for therapeutics targeting TLT-1 or B7-H3, two clinically relevant molecules.

bioengineering↗

SETD2 maintains nuclear lamina stability to safeguard the genome

Histone methyltransferases play essential roles in the organization and function of chromatin. They are also frequently mutated in human diseases including cancer1. One such often mutated methyltransferase, SETD2, associates co-transcriptionally with RNA polymerase II and catalyzes histone H3 lysine 36 trimethylation (H3K36me3) - a modification that contributes to gene transcription, splicing, and DNA repair2. While studies on SETD2 have largely focused on the consequences of its catalytic activity, the non-catalytic functions of SETD2 are largely unknown. Here we report a catalysis-independent function of SETD2 in maintaining nuclear lamina stability and genome integrity. We found that SETD2, via its intrinsically disordered N-terminus, associates with nuclear lamina proteins including lamin A/C, lamin B1, and emerin. Depletion of SETD2, or deletion of its N-terminus, resulted in widespread nuclear morphology abnormalities and genome stability defects that were reminiscent of a defective nuclear lamina. Mechanistically, the N-terminus of SETD2 facilitates the association of the mitotic kinase CDK1 with lamins, thereby promoting lamin phosphorylation and depolymerization required for nuclear envelope disassembly during mitosis. Taken together, our findings reveal an unanticipated link between the N-terminus of SETD2 and nuclear lamina organization that may underlie how SETD2 acts as a tumor suppressor.

cell biology↗